Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 15/20 | 0.66 |
| ▸ | ERCC4 | Q92889 | 15/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | ARG1 | P05089 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138689 | 0.89 | MAPT (0.66) | ERCC1ERCC4TRPV1ALPL | |
| SCHEMBL107288 | 0.88 | ERCC1 (0.66) | ERCC1ERCC4TRPV1ALPGARG1 | |
| SCHEMBL108218 | 0.86 | ERCC1 (0.78) | ERCC1ERCC4LCKTRPV1ARG1 | |
| SCHEMBL8269527 | 0.84 | KDM4E (0.69) | ERCC1ERCC4TRPV1ALPGALPL | |
| SCHEMBL107165 | 0.84 | ERCC1 (0.73) | ERCC1ERCC4TRPV1 | |
| SCHEMBL10067938 | 0.83 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL10038329 | 0.83 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL107880 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4TRPV1 | |
| SCHEMBL107237 | 0.82 | ERCC1 (0.81) | ERCC1ERCC4TRPV1 | |
| SCHEMBL108637 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | claimed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | claimed |
| US-20030139470-A1 | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants | HAARMANN & REIMER GMBH (DE) | 2003-07-24 | — | — | US | claimed |
| US-20030139470-A1 | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants | HAARMANN & REIMER GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | ERCC1 3561/4885ERCC4 4660/4885LCK 1795/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | ERCC1 2754/4885ERCC4 3932/4885LCK 1680/4885 |
| US-20030139470-A1 | 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants | TYR, HAAO, TH | ERCC1 2276/4885ERCC4 2029/4885LCK 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.